Williams Kristen sold 10,259 shares of Pacira BioSciences, Inc. at $22.27 for −$228k on Jun 4, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Administrative Officer
Chief Administrative Officer
Filed Jun 5, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$228,467.93Shares × reported price
Shares traded
10,259Common Stock
Price per share
$22.27Reported price. Read footnotes for ranges.
% of reported position traded
5.79%This security and ownership context
Holdings after
167,062Direct
Trade date
Jun 4, 2026Sell
Filed
Jun 5, 2026, 5:57 PM ET1-day reporting delay
Accession
0001628280-26-041330Code S · Transaction 98947
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 177,321 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Jun 3, 2026Tax withholding8,528$22.32−$190,344.96Trade 98946
2 transaction rows in this filing. Joint filers share the same rows.

PCRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
PCRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +9%1w ago +4.1%1d ago −1.9%
Returns since7d +1.1%30d +12%90d180d1y

Footnotes in full

F1: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025.